FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| INSMED (NASDAQ: INSM) | Delayed: 95.06 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $95.06 | 52 Week High | $19.30 | |||
| Open | $95.06 | 52 Week Low | $9.02 | |||
| Day High | $95.06 | P/E | N/A | |||
| Day Low | $95.06 | EPS | $-1.69 | |||
| Volume | 12,092 | |||||
